WO2013107283A1 - Benzoheterocyclic compounds and use thereof - Google Patents

Benzoheterocyclic compounds and use thereof Download PDF

Info

Publication number
WO2013107283A1
WO2013107283A1 PCT/CN2013/000037 CN2013000037W WO2013107283A1 WO 2013107283 A1 WO2013107283 A1 WO 2013107283A1 CN 2013000037 W CN2013000037 W CN 2013000037W WO 2013107283 A1 WO2013107283 A1 WO 2013107283A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
salt
fluoro
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2013/000037
Other languages
English (en)
French (fr)
Inventor
Hongqi Tian
Conghui JI
Chunlei Liu
Li Kong
Ying Cheng
Gongchao HUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANJIN BINJIANG PHARMA Inc
Original Assignee
TIANJIN BINJIANG PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIANJIN BINJIANG PHARMA Inc filed Critical TIANJIN BINJIANG PHARMA Inc
Priority to AU2013201455A priority Critical patent/AU2013201455B8/en
Priority to US14/372,731 priority patent/US9290468B2/en
Priority to CA2897259A priority patent/CA2897259C/en
Priority to NZ627631A priority patent/NZ627631A/en
Priority to EP13738359.2A priority patent/EP2804855B1/en
Priority to JP2014551508A priority patent/JP6077006B2/ja
Priority to HK15103824.9A priority patent/HK1203486B/en
Publication of WO2013107283A1 publication Critical patent/WO2013107283A1/en
Anticipated expiration legal-status Critical
Priority to US15/050,045 priority patent/US9937158B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Definitions

  • benzothiadiazole benzoxazole and benzothiazole derivatives, which are inhibitors of protein kinases such as MEK.
  • the compounds may be useful in the treatment of conditions or disorders where the MEK cascade is implicated such as cancer and inflammatory diseases.
  • X 1 is CR 11 or N
  • each R b , R c and R d is independently hydrogen or C1-C10 alkyl
  • Kits comprising a compound as described herein and instructions for use are also provided.
  • kits for the treatment or prevention in an individual of a disease or condition mediated by MEK comprising any one of the compounds detailed herein or a pharmaceutically acceptable salt, solvate, or prodrug thereof; and packaging.
  • the kit comprises a formulation of any one of the compounds described herein and packaging.
  • X 2 is O, S or carbonyl
  • each R 7 and R 8 is independently hydrogen, C 1 -C 10 alkyl, C 2 -Cio alkenyl, C 2 -Cio alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkyl C1-C10 alkyl or C1-C10 alkyl C3-C10 cycloalkyl;
  • the compound is of the formula (I), or a salt, prodrug or solvate thereof, wherein X 2 is O, S or carbonyl. In some embodiments, X 2 is S. In some embodiments, X 2 is O. In some embodiments, X 2 is carbonyl.
  • the compound is of the formula (I), or a salt, prodrug or solvate thereof, wherein R 3 is hydrogen, halo, cyano, nitro, azido, hydroxy, C 1 -C 10 alkoxy, halo- substituted C1-C10 alkoxy, acyloxy, mercapto, C1-C10 alkylthio, halo-substituted C1-C10 alkylthio, -S0 2 R a , -S0 2 N(R c )R d , -N(R c )R d , -C(0)OR b , C 1 -C 10 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl or C 3 -C 10 cycloalkyl.
  • R 3 is halo or cyano.
  • R 3 is halo (e.g.
  • R 6 is -C(0)N(R 8 )OR 7 , -C(0) R 7 R 8 or - HS0 2 R 10 ; each R 7 and R 10 is independently C 1 -C4 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 cycloalkyl Ci-C 4 alkyl or Ci-C 4 alkyl C 3 -C 4 cycloalkyl, where each of the Ci-C 4 alkyl, C 3 -C 4 cycloalkyl, C 3 -C 4 cycloalkyl Ci-C 4 alkyl or Ci- C 4 alkyl C 3 -C 4 cycloalkyl groups may be unsubstituted or substituted with 1 to 6 hydroxy groups; and R 8 is hydrogen or Ci-C 4 alkyl.
  • R 3 is hydrogen, halo, cyano, nitro, azido, hydroxy, C 1 -C 10 alkoxy, halo-substituted Ci- C 10 alkoxy, mercapto, C 1 -C 10 alkylthio, halo-substituted C 1 -C 10 alkylthio, carboxy, -OC(0)H, amino, C1-C10 alkyl, C 2 -Cio alkenyl, C 2 -Cio alkynyl or C3-C10 cycloalkyl;
  • the compound is of the formula (1-3), (I-3-a), (I-3-b), (I-3-c) or (1-3 -d), or a salt, prodrug or solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 11 , where applicable, are as defined for the formula (I) or any applicable variations thereof.
  • R 3 is halo (e.g., iodo or bromo), substituted C 1 -C 10 alkyl (e.g., trifluoromethyl), halo-substituted Ci-Cio alkoxy (e.g., trifluoromethoxy), Ci-Cio alkylthio (e.g., methylthio), -S0 2 R a , -S0 2 N(R c )R d , -N(R c )R d or -C(0)OR b .
  • halo e.g., iodo or bromo
  • substituted C 1 -C 10 alkyl e.g., trifluoromethyl
  • halo-substituted Ci-Cio alkoxy e.g., trifluoromethoxy
  • Ci-Cio alkylthio e.g., methylthio
  • R 5 is hydrogen, halo (e.g., fluoro) or Ci-Cio alkyl (e.g., methyl).
  • R 7 is Ci-Cio alkyl substituted with at least one hydroxy group.
  • R 7 is Ci-Cio alkyl substituted with at least 1 to 3 hydroxy groups.
  • R 7 is Ci-C 6 alkyl substituted with at least 1 to 3 hydroxy groups.
  • R 1 , R 3 , R 5 , R 7 and R 11 are as defined for the formula (J), (I) or any variations thereof.
  • R 3 is -S0 2 R a where R a is unsubstituted or substituted Ci-Cio alkyl (e.g., S0 2 Me).
  • R 3 is -N(R c )R d where R c and R d are independently hydrogen or Ci-Cio alkyl (e.g., Me 2 ).
  • R 3 is -C(0)OR b where R b is unsubstituted or substituted Ci-Cio alkyl (e.g., C0 2 Me).
  • X is N and X is S.
  • X is S and X is CR where R is hydrogen, Ci-Cio alkyl, C 2 -Cio alkenyl, C 2 -Cio alkynyl, C 3 -Cio cycloalkyl or C 3 -Cio cycloalkyl Ci-Cio alkyl.
  • Typical solvents are as defined above and prefer dioxane.
  • Typical solvents are as defined above and prefer N,N-dimethylformamide and N,N- dimethylacetamide.
  • Typical solvents are as defined above and prefer dichloromethane, THF, MeOH and DMF.
  • Typical solvents are as defined above and prefer anhydrous THF.
  • the compound of formula (X-XIII) can be prepared from the reaction of the compound of formula (X-II) with azide in the presence of base in appropriate solvent.
  • Typical bases include, but are not limited to, inorganic base (such as Na 2 C0 3 , K 2 C0 3 , NaHC0 3 , KHC0 3 , f BuONa and f BuOK) and organic base (such as diethylamine, triethylamine and pyridine) and prefer triethylamine.
  • inorganic base such as Na 2 C0 3 , K 2 C0 3 , NaHC0 3 , KHC0 3 , f BuONa and f BuOK
  • organic base such as diethylamine, triethylamine and pyridine
  • Typical bases include, but are not limited to, Na 2 C0 3 , K 2 C0 3 , NaHC0 3 , KHC0 3 , tBuOK, and tBuONa.
  • Benzyl 5-(benzyloxy)-3,4-difluoro-2-((2-fluorophenyl)amino) benzoate can be reacted with azide (such as NaN 3 , KN 3 ) in appropriate solvent.
  • azide such as NaN 3 , KN 3
  • the reaction generally is carried out at high temperature (60-120 °C, prefer 80-100 °C) and normally completes within several hours (1- 12 h, prefer 3-10 h).
  • the desired product is obtained after conventional workup.
  • Benzyl 4-azido-5-(benzyloxy)-3-fluoro-2-((2-fluorophenyl)amino) benzoate can be hydrogenated in the presence of appropriate catalyst (such as Pd/C, Pt, Ni). The reaction normally completes within several hours (1-12 h, prefer 3-10 h). 4-Amino-3-fluoro-2-((2- fluorophenyl) amino)-5-hydroxybenzoic acid is obtained after conventional workup.
  • appropriate catalyst such as Pd/C, Pt, Ni
  • Typical solvents are as defined above and prefer methanol, ethanol, propan-l-ol and water.
  • Typical acids include ⁇ -toluenesulfonic acid, pyridinium toluene-4-sulphonate, formic acid, acetic acid and sulfuric acid.
  • 4-Fluoro-5-((2-fluorophenyl)amino)benzo[d]oxazole-6-carboxylic acid can be reacted with halogenations reagent (such as NIS) under acidic condition in appropriate solvent.
  • halogenations reagent such as NIS
  • the reaction generally is carried out at ambient temperature and normally completes within several hours (1-12 h, prefer 3-10 h).
  • 4-Fluoro-5-((2-fluoro-4- iodophenyl)amino)benzo[d]oxazole-6- carboxylic acid is obtained after conventional workup.
  • Typical coupling reagents include, but are not limited to 1 -Hydroxy- lH-benzotriazole (HOBt), 3 -(ethyliminomethyleneamino)-N,N-dimethylpropan- 1 -amine(EDCI), 0-(7- azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and O- Benzotriazol-l-yl-N,N,N',N'- tetramethyluronium tetrafluoroborate (TBTU).
  • HOBt 1 -Hydroxy- lH-benzotriazole
  • EDCI 3 -(ethyliminomethyleneamino)-N,N-dimethylpropan- 1 -amine(EDCI)
  • EDCI 0-(7- azabenzotriazol-l-yl)-N,
  • Typical halogenation reagents include, but are not limited to NCS, NBS, NIS and so on.
  • Typical acids include, but are not limited to, trifluoroacetic acid,
  • Said tri(Ci-C 6 alkyl) orthoformate includes trimethoxymethane and triethoxy methane.
  • Typical bases include, but are not limited to, inorganic base (such as Na 2 C0 3 , K 2 C0 3 , NaHC0 3 , KHC0 3 , f BuONa and f BuOK) and organic base (such as diethylamine, triethylamine, pyridine and potassium trimethylsilanolate) and prefer potassium trimethylsilanolate.
  • inorganic base such as Na 2 C0 3 , K 2 C0 3 , NaHC0 3 , KHC0 3 , f BuONa and f BuOK
  • organic base such as diethylamine, triethylamine, pyridine and potassium trimethylsilanolate
  • prefer potassium trimethylsilanolate prefer potassium trimethylsilanolate.
  • Typical solvents are as defined above and prefer anhydrous THF, ethyl ether and dioxane).
  • Typical solvents are as defined above and prefer anhydrous THF, ethyl ether and dioxane).
  • Typical phosphine ligands include, but are not limited to,
  • dimethylbisdiphenylphosphinoxanthene tri-tert-butylphosphine, tri-p-tolylphosphine, tris(4- chlorophenyl)phosphine, triisopropylphosphine, tris(2,6-dimethoxyphenyl)phosphine, 1, 1 '-bis (diphenylphosphino)ferrocene and preferably select dimethylbisdiphenyl phosphinoxanthene.
  • Typical solvents are as defined above and prefer dioxane.
  • Methyl 3,4-difluoro-2-((2-fluorophenyl)amino)-5-((4-methoxy benzyl)thio)benzoate can be reacted with azide (such as NaN 3 , KN 3 ) in appropriate solvent.
  • the reaction is generally carried out at high temperature (60-120 °C, prefer 80-100 °C) and normally completes within several hours (1-12 h, prefer 3-10 h).
  • Methyl 4-azido-3-fluoro-2-((2-fluorophenyl)amino)-5-((4- methoxybenzyl)thio)benzoate is obtained after conventional workup.
  • 5,5'-Disulfanediylbis(4-amino-3-fluoro-2-((2-fluorophenyl)amino)benzoate) can be prepared from methyl 4-amino-3-fluoro-2-((2-fluoro phenyl)amino)-5-((4- methoxybenzyl)thio)benzoate by deprotection in appropriate solvent.
  • the desired product is obtained after conventional workup.
  • Typical solvents are as defined above and prefer dichloromethane, chloroform, MeOH and EtOH.
  • Said reductive reagents include NaBH 4 , NaC BH 3 , NaBH(OAc) 3 , Zn powder and Fe powder.
  • Typical solvents are as defined above and prefer the mixture of THF and MeOH. Step 3.1.9
  • Methyl 4-amino-3-fluoro-2-((2-fluorophenyl)amino)-5-mercapto benzoate can be cyclized in the presence of acid in appropriate solvent. The reaction normally completes within several hours (0.2-12 h, prefer 0.5-10 h). Methyl 4-fluoro-5-((2-fluorophenyl)amino)benzo [d]thiazole-6-carboxylate is obtained after conventional workup.
  • Typical acids include, but are not limited to ⁇ -toluenesulfonic acid, pyridinium toluene-4-sulphonate, formic acid, acetic acid and sulfuric acid.
  • Methyl 4-fluoro-5-((2-fluorophenyl)amino)benzo[d]thiazole-6- carboxylate can be reacted with halogenations reagent (such as NIS) in the presence of acid at ambient temperature in appropriate solvent. The reaction normally completes within several hours (1-12 h, prefer 3- 10 h). Methyl 4-fluoro-5-((2-fluoro-4-iodophenyl)amino)benzo [d]thiazole-6-carboxylate is obtained after conventional workup.
  • halogenations reagent such as NIS
  • Typical acids include, but are not limited to, trifluoroacetic acid,
  • Typical solvents are as defined above and prefer N,N-dimethylformamide and N,N- dimethylacetamide.
  • 4-Fluoro-5-((2-fluoro-4-iodophenyl)amino)benzo[d]thiazole-6-carboxylic acid can be prepared from methyl 4-fluoro-5-((2-fluoro-4-iodo phenyl)amino)benzo[d]thiazole-6- carboxylate be deprotection in appropriate solvent.
  • Typical deprotection reagents may be base, Pd/C, Lewis acid or R 4 F.
  • Said base includes, but are not limited to, NaOH, KOH, Na 2 C0 3 and K 2 C0 3 .
  • Coupling reagents include, but are not limited to, HOBt, EDCI, HATU and TBTU.
  • Typical solvents are as defined above and prefer dichloromethane, 1,2-dichloroethane and N,N-dimethylformamide.
  • Typical acids include, but not limited to, hydrochloric acid, sulfuric acid and trifluoroacetic acid.
  • Typical solvents are as defined above and prefer dichloromethane and 1,2- dichloroethane.
  • a compound of the formula (1-3 -a), i.e., a compound of the formula (I) where X 1 is CR 11 , X 2 is S and R 6 is -C(0)N(R 8 )OR 7 , where R 3 is halo may be synthesized according to
  • the compound of formula (I-3-a) can be prepared from the reaction of the compound of formula (Z-II) with hydroxylamine (R 7 OR 8 H) in the presence of coupling reagents in appropriate solvent.
  • Typical coupling reagents include, but are not limited to 1 -Hydroxy- lH-benzotriazole (HOBt), 3-(ethyliminomethyleneamino)-N,N-dimethylpropan- 1 -amine(EDCI), 0-(7- azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and O- Benzotriazol-l-yl-N,N,N',N'- tetramethyluronium tetrafluoroborate (TBTU).
  • HOBt 1 -Hydroxy- lH-benzotriazole
  • EDCI 3-(ethylimi
  • Typical solvents are as defined above and prefer dichloromethane, 1,2-dichloroethane, THF and N,N-dimethylformamide.
  • Typical deprotection reagents may be base, Pd/C, Lewis acid or R 4 F according to different R 14
  • Said base includes, but are not limited to, NaOH, KOH, Na 2 C0 3 , K 2 C0 3 .
  • Said Lewis acids include, but are not limited to A1C1 3 , BF 3 and BBr 3 .
  • Typical solvents are as defined above and prefer dichloromethane, THF, MeOH and
  • the compound of formula (Z-III) where R 3 is halo can be prepared from halogenation of the compound of formula (Z-IV) in the presence of halogenation reagents and acid in appropriate solvent.
  • Typical halogenation reagents include, but are not limited to NCS, NBS, NIS and so on.
  • Typical catalysts include, but are not limited to 4-dimethylaminopyridine (DMAP).
  • R , R , R J , R , R , R', R° and R are as defined for the formula (J), (I) or any variations thereof, and R 14 is hydrogen, benzyl, benzyl substituted with 1 to 3 methoxy groups, C 1 -C5 alkyl or -SiR 16 R 17 R 18 where R 16 , R 17 and R 18 are independently selected from C 1 -C 10 alkyl and C 6 -Ci 4 aryl.
  • the method further comprises converting a compound of the formula (F-3a) or a salt thereof to the compound of the formula (G-3a) or a salt thereof:
  • the method comprises reacting an orthoester of formic acid with a compound of the formula (F-3a) or a salt thereof.
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 7 are as defined for the formula (J), (I) or any variations thereof, provided that R 3 is other than halo; and each R 14 and R 15 is independently allyl, benzyl, benzyl substituted with 1 to 3 methoxy groups, C1-C5 alkyl or -SiR 16 R 17 R 18 where R 16 , R 17 and R 18 are independently selected from Ci-Cio alkyl and C 6 -Ci4 aryl.
  • R 3 is H, halogen, cyano, nitro, azido, -OR 7 , -SR 7 , -C(0)R 7 , -C(0)OR 7 , - R 8 C(0)OR 10 , - OC(0)R 7 , - R 8 S0 2 R 10 , -S0 2 R 7 R 8 , - R 8 C(0)R 7 , -C(0) R 7 R 8 , - R 9 C(0) R 7 R 8 , - R 9 C(NCN) R 7 R 8 , - R 7 R 8 , Ci-Cio alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, C 3 -Ci 0 cycloalkyl, (C3-C10 cycloalkyl)Ci-Cio alkyl, -S(0)j(Ci-Cio alkyl), -S(0) j (CR 8 R 9 ) m C 6 -C
  • each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl portions is optionally substituted with one or more groups independently selected from oxo-, halogen, cyano, nitro, -CF 3 , azido, -OR 7 , -C(0)R 7 , -C(0)OR 7 , - R 8 C(0)OR 10 , -OC(0)R 7 , - R 8 S0 2 R 10 , -S0 2 R 7 R 8 , - R 8 C(0)R 7 , -C(0) R 7 R 8 , - R 9 C(0) R 7 R 8 , - R 9 C(NCN) R 7 R 8 , - R 7 R 8 , C 6 -Ci 4 aryl, (C 6 -C 14 aryl)Ci-Ci 0 alkyl, heteroaryl, heteroaryl(Ci-Ci 0 alkyl),
  • R 7 and R 8 together with the atom to which they are attached, form a substituted or unsubstituted 3- to 10- member ring; wherein each group is optionally substituted with one or more substituents independently selected from halogen, cyano, nitro, -CF 3 , azido, - R'S0 2 R"", - S0 2 R'R", -C(0)R', -C(0)OR', -OC(0)R', - R'C(0)R"", - R'C(0)R", -C(0) R'R”, -SR', - S(0)R"", -S0 2 R"", - R'R", - R'C(0) R"R"', - R'C(NCN) R"R'", -OR', C 6 -Ci 4 aryl, heteroaryl, (C 6 -Ci 4 aryl)Ci-Cio alkyl, (heteroaryl)Ci-Cio alkyl, heterocycl
  • R 10 is H, Ci-Cio alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, C 3 -Ci 0 cycloalkyl, (C 3 -C 10 cycloalkyl)Ci-Cio alkyl, C 6 -Ci 4 aryl, (C 6 -C 14 aryl)Ci-Cio alkyl, heteroaryl, (heteroaryl)Ci-Cio alkyl, heterocycloalkyl or (heterocycloalkyl)Ci-Cio alkyl;
  • each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl is optionally substituted with one or more groups independently selected from oxo-, halogen, cyano, nitro, -CF 3 , azido, -NR'S0 2 R"", -S0 2 NR'R", -C(0)R', -C(0)OR', -OC(0)R', - NR'C(0)R"", -NR'C(0)R", -C(0)NR'R", -SR', -S(0)R"", -S0 2 R"", -NR'R", -NR'C(0)NR"R"', -NR'C(NCN)NR"R”', -OR', C 6 -Ci 4 aryl, heteroaryl, (C 6 -C 14 aryl)Ci-Ci 0 alkyl, (heteroaiyl)Ci- Cio
  • R', R" and R'" are independently H, Ci-Cio alkyl, C 2 -C 6 alkenyl, C 6 -Ci 4 aryl, or (C 6 -C 14 aryl)Ci-Cio alkyl;
  • X 1 is CR 11 or N
  • j 0, 1 or 2.
  • each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl is optionally substituted with one or more groups independently selected from oxo-, halogen, cyano, nitro, -CF 3 , azido, - R'S0 2 R"", -S0 2 R'R", -C(0)R', -C(0)OR', -OC(0)R', - R'C(0)R"", - R'C(0)R", -C(0) R'R", -SR', -S(0)R"", -S0 2 R"", - R'R", - R'C(0) R"', - R'C(NCN) R"R'", -OR', C 6 -Ci 4 aryl, heteroaryl, (C 6 -C 14 aryl)Ci-Ci 0 alkyl, (heteroaiyl)Ci- C10 alkyl
  • R', R" and R'" are independently hydrogen, C1-C10 alkyl, C 2 -C 6 alkenyl, C 6 -Ci 4 aryl, or (C 6 -Ci 4 aryl)Ci-Cio alkyl;
  • Especially preferred X 1 is CR 11 or N;
  • Particularly preferred X 1 is CR 11 or N.
  • R 11 is H, Ci-C 6 alkyl or (C 3 -C 8 cycloalkyl)Ci-C 6 alkyl;
  • R 11 is H or Ci-C 4 alkyl
  • R 11 is H.
  • heterocycloalkyl and (heterocycloalkyl)Ci-Cio alkyl;
  • R 1 is H, fluoro, chloro, bromo, Ci-C 4 alkyl, halogenated Ci-C 4 alkyl, halogenated Ci-C 4 alkoxy;
  • R 1 is fluorine, chlorine, methyl, -CF 3 , -CF 3 0.
  • R 2 is H, halogen or Ci-C 6 alkyl
  • R 2 is H, halogen or Ci-C 4 alkyl
  • R 5 is H, fluorine, chlorine or methyl.
  • Preferred R 3 is H, halogen, Ci-Cio alkoxy, Ci-Cio alkyl sulphanyl, halogenated Ci-Cio alkoxy, halogenated Ci-Cio alkylsulphanyl or halogenated Ci-Cio alkyl;
  • R 3 is fluoro, chloro, bromo, iodo, Ci-C 6 alkoxy, Ci-C 6 alkyl sulphanyl, halogenated Ci-C 6 alkoxy, halogenated Ci-C 6 alkylsulphanyl or halogenated Ci-C 6 alkyl;
  • R 3 is bromo, iodo, -SCH 3 , -OCF 3 , -CF 3 .
  • R 6 is -C(0) R 8 OR 7 or -C(0) R 8 R 7 ;
  • each of R 7 , R 8 and R 9 is independently H, C 1 -C 1 0 alkyl, C 2 -C 1 0 alkenyl, C 2 -C 1 0 alkynyl, C 3 -Cio cycloalkyl, (C 3 -C 10 cycloalkyl)Ci-Ci 0 alkyl, C 6 -Ci 4 aryl, (C 6 -C 14 aryl)Ci-Ci 0 alkyl, heteroaryl, (heteroaryl)Ci-Cio alkyl, heterocycloalkyl or (heterocycloalkyl)Ci-Cio alkyl;
  • each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl is optionally substituted with one or more groups independently selected from hydroxyl, oxo-, halogen, cyano, nitro, -CF 3 , azido, - R'S0 2 R"", -S0 2 R'R", -C(0)R', -C(0)OR', -OC(0)R', - R'C(0)R"", - R'C(0)R", -C(0) R'R", -SR', -S(0)R"", -S0 2 R"", - R'R", - R'C(0) R"', - R'C(NCN) R"R'", -OR', C 6 -Ci 4 aryl, heteroaryl, (C 6 -C 14 aryl)Ci-Ci 0 alkyl, (heteroaiyl)Ci- C
  • R 7 and R 8 together with the atom to which they are attached, form a substituted or unsubstituted 3- to 10- member ring; wherein each group is optionally substituted with one or more substituents independently selected from halogen, cyano, nitro, -CF 3 , azido, - R'S0 2 R"", - S0 2 R'R", -C(0)R', -C(0)OR', -OC(0)R', - R'C(0)R"", - R'C(0)R", -C(0) R'R”, -SR', - S(0)R"", -S0 2 R"", -NR'R", -NR'C(0)NR"R”', -NR'C(NCN)NR"R”', -OR', C 6 -d 4 aryl, heteroaryl, (C 6 -Ci 4 aryl)Ci-Cio alkyl, (heteroaryl)Ci-Cio alkyl, heterocycl
  • R 8 and R 9 together with the atom to which they are attached, form a substituted or unsubstituted 3- to 10- member ring; wherein each group is optionally substituted with one or more substituents independently selected from halogen, cyano, nitro, -CF3, azido, -NR'S0 2 R"", -S0 2 NR'R", -C(0)R', -C(0)OR', -OC(0)R', -NR'C(0)R"", -NR'C(0)R", -C(0)NR'R", -SR', - S(0)R"", -S0 2 R"", -NR'R", -NR'C(0)NR"R”', -NR'C(NCN)NR"R”', -OR', C 6 -Ci 4 aryl, heteroaryl, (C 6 -Ci 4 aryl)Ci-Cio alkyl, (heteroaryl)Ci-Cio alkyl, heterocycl
  • R is hydrogen, Ci-Cio alkyl, C2-C10 alkenyl, C 2 -Cio alkynyl, C3-C10 cycloalkyl, (C 3 -C 10 cycloalkyl)Ci-Cio alkyl, C 6 -Ci 4 aryl, (C 6 -C 14 aryl)Ci-Cio alkyl, heteroaryl, (heteroaryl)Ci-Cio alkyl, heterocycloalkyl or (heterocycloalkyl)Ci-Cio alkyl;
  • R', R" and R'" are independently hydrogen, C1-C10 alkyl, C 2 -C 6 alkenyl, C 6 -Ci 4 aryl, or (C 6 -Ci4 aryl)Ci-Cio alkyl;
  • R" is C1-C10 alkyl, C 2 -C 6 alkenyl, C 6 -Ci 4 aryl or (C 6 -C 14 aryl)Ci-Ci 0 alkyl;
  • R 6 is -C(0) R 8 OR 7 or -C(0) R 8 R 7 ;
  • R 7 is Ci-C 6 alkyl substituted with 1 to 6 hydroxy groups, or (C 3 -Cio cycloalkyl)Ci-Cio alkyl;
  • R 8 is hydrogen or Ci-C 6 alkyl.
  • R 6 is -C(0) R 8 OR 7 or -C(0) R 8 R 7 ;
  • R 7 is ethyl, propyl or isobutyl substituted with 1 to 3 hydroxy groups, or (C 3 -C 6 cycloalkyl) Ci-C 4 alkyl.
  • the compound is of the formula (A-I), where X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined for the preferred variations for the X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 groups described above.
  • the compound is of the formula (A-I), where X 1 ,
  • X R , R R J , R R J and R° are as defined for the more preferred variations for the X , X , R , R 2 , R 3 , R 4 , R 5 and R 6 groups described above.
  • the compound is of the formula (A-I), where X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined for the especially preferred variations for the X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 groups described above.
  • the compound is of the formula (A-I), where X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined for the particularly preferred variations for the X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 groups described above.
  • Saturated or unsaturated hydrocarbon radicals e.g., Ci-Cio alkyl, alkylene or alkenyl
  • a heteroatom e.g., alkoxy
  • any groups may be optionally substituted with a single substituent or with multiple substituents, and the substituents in a multiply substituted group may be the same or different.
  • dichloromethane 1,2-dichloroethane, chloroform, phenixin, chlorobenzene, o-dichlorobenzene
  • ether such as diethyl ether, dibutyl ether, glycol dimethyl ether, 2-methoxyethyl ether, tetrahydrofuran, dioxane
  • ketone such as acetone, methyl ethyl ketone, methyl isopropyl ketone, methyl isobutyl ketone
  • ester such as ethyl acetate, methyl acetate
  • nitrile such as acetonitrile, propiononitrile
  • amide such as N,N-dimethylformamide, N,N-dimethylacetamide and N- methylpyrrolidin-2-one
  • DMSO sulfolane
  • HMPA methyl ethyl ketone
  • DMSO sulfolane
  • l-benzyloxy-2,3,4-trifluorobenzene in appropriate inert solvent (such as, but not limited to, aliphatic and aromatic hydrocarbon (such as pentane, hexane, heptane, cyclohexane, petroleum ether, petrol, gasoline, benzene, toluene, xylene), ether (such as diethyl ether, dibutyl ether, glycol dimethyl ether, 2-methoxyethyl ether, tetrahydrofuran, dioxane), sulfolane, HMPA, DMPU, prefer anhydrous THF, ethyl ether and dioxane) was added strong base (such as LDA, n-BuLi, LiHDMS) at low temperature (-50 °C - -80 °C, prefer -78 °C) under nitrogen atmosphere.
  • solvent such as, but not limited to, aliphatic and aromatic hydrocarbon (such as
  • 5-Benzoxy-2,3,4-trifluorobenzoic acid can be reacted with halogenated aniline (such as o-fluoroaniline, o-chloroaniline, o-bromoaniline, o-iodoaniline) under strong basic
  • 5-(Benzyloxy)-3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid can be protected by acid or hydroxyl protection reagent(such as BnBr, BnCl) at ambient temperature in the presence of base (includes Na 2 C0 3 , K 2 C0 3 , NaHC0 3 , KHC0 3 , t-BuOK, t-BuONa) in appropriate inert solvent(include aliphatic and aromatic hydrocarbon(such as pentane, hexane, heptane, cyclohexane, petroleum ether, petrol, gasoline, benzene, toluene, xylene), aliphatic and aromatic halo-hydrocarbon (such as dichloromethane, 1,2-dichloroethane, chloroform, phenixin, chlorobenzene, o-dichlorobenzene), ether (such as diethyl ether
  • Benzyl 5-(benzyloxy)-3,4-difluoro-2-((2-fluorophenyl)amino) benzoate can be reacted with azide (such as NaN 3 , KN 3 ) in appropriate solvent(include aliphatic and aromatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PCT/CN2013/000037 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof Ceased WO2013107283A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2013201455A AU2013201455B8 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
US14/372,731 US9290468B2 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
CA2897259A CA2897259C (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
NZ627631A NZ627631A (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
EP13738359.2A EP2804855B1 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
JP2014551508A JP6077006B2 (ja) 2012-01-17 2013-01-16 ベンゾ複素環式化合物およびその使用
HK15103824.9A HK1203486B (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
US15/050,045 US9937158B2 (en) 2012-01-17 2016-02-22 Benzoheterocyclic compounds and use thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201210014021.X 2012-01-17
CN201210014021 2012-01-17
CN201210189087.2 2012-06-08
CN201210190520.4 2012-06-08
CN201210189086.8A CN103204822B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CN201210189087.2A CN103204827B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
CN201210190520.4A CN103204825B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
CN201210189086.8 2012-06-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/372,731 A-371-Of-International US9290468B2 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
US15/050,045 Division US9937158B2 (en) 2012-01-17 2016-02-22 Benzoheterocyclic compounds and use thereof

Publications (1)

Publication Number Publication Date
WO2013107283A1 true WO2013107283A1 (en) 2013-07-25

Family

ID=48752254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/000037 Ceased WO2013107283A1 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof

Country Status (7)

Country Link
US (2) US9290468B2 (enExample)
EP (1) EP2804855B1 (enExample)
JP (1) JP6077006B2 (enExample)
CN (3) CN103204827B (enExample)
CA (1) CA2897259C (enExample)
NZ (1) NZ627631A (enExample)
WO (1) WO2013107283A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710417B (zh) * 2013-12-11 2020-09-08 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN105859543A (zh) * 2016-05-06 2016-08-17 蚌埠中实化学技术有限公司 一种2,6-二氟-4-溴苯甲酰氯的制备方法
CN111205244B (zh) * 2018-11-22 2023-08-18 上海科技大学 噻唑并环类化合物、其制备方法、中间体和应用
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
EP4663631A1 (en) * 2023-02-10 2025-12-17 Shanghai Kechow Pharma, Inc. Polymorph as protein kinase mek inhibitor, and preparation method therefor and use thereof
WO2025242163A1 (zh) * 2024-05-23 2025-11-27 上海科州药物股份有限公司 蛋白激酶mek抑制剂的盐及其用途

Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043960A1 (en) 1997-04-03 1998-10-08 American Cyanamid Company Substituted 3-cyano quinolines
WO1999001421A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
WO1999001426A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
WO2000041003A1 (en) 1998-12-31 2000-07-13 General Electric Company Ultrasound color flow display optimization by adjustment of threshold
WO2000041994A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
WO2000042029A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
WO2000041505A2 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Anthranilic acid derivatives
WO2000042002A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
WO2000042022A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
WO2000068201A1 (en) 1999-05-08 2000-11-16 Astrazeneca Ab Quinoline derivatives as inhibitors of mek enzymes
WO2001068619A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
WO2005023759A2 (en) 2003-09-03 2005-03-17 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2005023251A1 (en) 2003-08-29 2005-03-17 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005046665A1 (en) 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
WO2005051302A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
WO2007014011A2 (en) 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2007044084A2 (en) 2005-05-18 2007-04-19 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2007071951A1 (en) 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
WO2007121481A2 (en) 2006-04-18 2007-10-25 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
CN101213196A (zh) * 2005-07-01 2008-07-02 赛诺菲-安万特 吡啶并[2,3-d]嘧啶衍生物，它们的制备，在治疗中的用途
WO2008078086A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Combination of an mek inhibitor and the src kinase inhibitor azd0530 for use in the treatment of cancer
WO2008089459A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of mek
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2008125820A1 (en) 2007-04-13 2008-10-23 Astrazeneca Ab Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
US20080293785A1 (en) * 2006-04-11 2008-11-27 Connolly Peter J Substituted benzothiazole kinase inhibitors
WO2009013426A2 (fr) 2007-07-13 2009-01-29 Societe Lemer Protection Anti-X Par Abreviation Societe Lemer Pax Materiau radioattenuateur, et procede pour l'obtention d'un tel materiau
WO2009018238A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009074827A2 (en) 2007-12-12 2009-06-18 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
WO2009093013A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Fused thiophene derivatives as mek inhibitors
WO2009093009A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Fused tricyclic thiophene derivatives as mek inhibitors
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2009153554A1 (en) 2008-06-19 2009-12-23 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
CN1358094A (zh) * 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
FR2911138B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
WO2008144767A1 (en) 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
FR2967672B1 (fr) 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use

Patent Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043960A1 (en) 1997-04-03 1998-10-08 American Cyanamid Company Substituted 3-cyano quinolines
WO1999001421A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
WO1999001426A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
WO2000041003A1 (en) 1998-12-31 2000-07-13 General Electric Company Ultrasound color flow display optimization by adjustment of threshold
WO2000041994A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
WO2000042029A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
WO2000041505A2 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Anthranilic acid derivatives
WO2000042002A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
WO2000042022A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
WO2000068201A1 (en) 1999-05-08 2000-11-16 Astrazeneca Ab Quinoline derivatives as inhibitors of mek enzymes
WO2001068619A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
WO2005023251A1 (en) 2003-08-29 2005-03-17 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005023759A2 (en) 2003-09-03 2005-03-17 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2005046665A1 (en) 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
WO2005051300A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
WO2005051302A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
WO2005051906A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2005051301A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2007044084A2 (en) 2005-05-18 2007-04-19 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
CN101213196A (zh) * 2005-07-01 2008-07-02 赛诺菲-安万特 吡啶并[2,3-d]嘧啶衍生物，它们的制备，在治疗中的用途
WO2007014011A2 (en) 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2007071951A1 (en) 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
US20080293785A1 (en) * 2006-04-11 2008-11-27 Connolly Peter J Substituted benzothiazole kinase inhibitors
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
WO2007121481A2 (en) 2006-04-18 2007-10-25 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008078086A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Combination of an mek inhibitor and the src kinase inhibitor azd0530 for use in the treatment of cancer
WO2008089459A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of mek
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2008125820A1 (en) 2007-04-13 2008-10-23 Astrazeneca Ab Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
WO2009013426A2 (fr) 2007-07-13 2009-01-29 Societe Lemer Protection Anti-X Par Abreviation Societe Lemer Pax Materiau radioattenuateur, et procede pour l'obtention d'un tel materiau
WO2009018238A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009074827A2 (en) 2007-12-12 2009-06-18 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
WO2009093013A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Fused thiophene derivatives as mek inhibitors
WO2009093009A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Fused tricyclic thiophene derivatives as mek inhibitors
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2009153554A1 (en) 2008-06-19 2009-12-23 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2804855A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Also Published As

Publication number Publication date
CN103204822A (zh) 2013-07-17
CN103204822B (zh) 2014-12-03
CA2897259A1 (en) 2013-07-25
AU2013201455B2 (en) 2015-07-23
US20160235721A1 (en) 2016-08-18
US9290468B2 (en) 2016-03-22
CN103204825B (zh) 2015-03-04
CN103204825A (zh) 2013-07-17
AU2013201455A8 (en) 2016-04-14
NZ627631A (en) 2016-10-28
CN103204827B (zh) 2014-12-03
HK1203486A1 (en) 2015-10-30
EP2804855A1 (en) 2014-11-26
EP2804855B1 (en) 2017-09-20
JP2015503597A (ja) 2015-02-02
AU2013201455A1 (en) 2013-08-01
CA2897259C (en) 2019-05-07
EP2804855A4 (en) 2015-07-29
US9937158B2 (en) 2018-04-10
AU2013201455C1 (en) 2016-01-21
CN103204827A (zh) 2013-07-17
US20140371278A1 (en) 2014-12-18
JP6077006B2 (ja) 2017-02-08

Similar Documents

Publication Publication Date Title
WO2013107283A1 (en) Benzoheterocyclic compounds and use thereof
ES3014444T3 (en) Bicyclic compounds
TWI504589B (zh) 作為香草類化合物受體之配體之經取代芳香族羧醯胺及尿素衍生物
CN106795103B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
JP5662143B2 (ja) 腫瘍の処置のためのＭｅｔキナーゼ阻害剤としての２−オキソ−３−ベンジルベンゾキサゾール−２−オン誘導体、および関連する化合物
JP5258563B2 (ja) αアミノ酸誘導体及びそれを有効成分として含む医薬
WO2013096771A1 (en) Non-systemic tgr5 agonists
TW201022283A (en) Fused imidazole carboxamides as TRPV3 modulators
JP2012512151A5 (enExample)
CA2689607A1 (en) Kinase inhibitor compounds
US20200223837A1 (en) Benzofuran amides and heteroaromatic analogues thereof for use in therapy
JP5174665B2 (ja) １−アシルジヒドロピラゾール誘導体
JP5334586B2 (ja) 置換５−フェニル−３，６−ジヒドロ−２−オキソ−６ｈ−［１，３，４］チアジアジン
WO2016098793A1 (ja) 環状グアニジル基を有するチアゾール誘導体
CN104119332A (zh) 作为蛋白激酶抑制剂的苯并杂环化合物及其制备方法和用途
AU2013201455B8 (en) Benzoheterocyclic compounds and use thereof
HK1203486B (en) Benzoheterocyclic compounds and use thereof
CN1820007A (zh) 经芳基取代的苯并[d]异噻唑－3－基胺类似物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2013201455

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13738359

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014551508

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14372731

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2013738359

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013738359

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2897259

Country of ref document: CA